Cidara Therapeutics: Strong Buy On Imminent Data Readout For Lead Flu Candidate

Group 1 - The company Cidara Therapeutics (NASDAQ: CDTX) is initiating coverage with a Strong Buy rating, indicating a positive outlook for the stock [1] - Cidara has shifted its focus from antifungal treatments to its proprietary Cloudbreak drug Fc conjugate platform, suggesting a strategic pivot in its business model [1]